Biocon in a regulatory filing on Tuesday said it sold 80,00,000 equity shares of its subsidiary Syngene International Ltd. (Syngene) in the open market for Rs.686 crore through a block deal.
Post this transaction, the shareholding of Biocon in Syngene shall stand at 52.46%. Prior to this transaction, Biocon held 54.45% stake in Syngene.
Syngene focusses on integrated research, development, and manufacturing services for global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors
ends
Published – December 10, 2024 08:01 pm IST
